Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies

被引：2
|
作者：
Bachelez, H. [1 ,2 ]
Griffiths, C. E. M. [3 ,4 ]
Papp, K. A. [5 ,6 ]
Hall, S. [7 ]
Merola, J. F. [8 ]
Feldman, S. R. [9 ]
Khraishi, M. [10 ]
Tan, H. [11 ]
Fallon, L. [12 ]
Cappelleri, J. C. [11 ]
Bushmakin, A. G. [11 ]
Young, P. [13 ]
机构：
[1] Hop St Louis, AP HP, Dept Dermatol, Paris, France
[2] Univ Paris, Imagine Inst, Unite INSERM U1163, Paris, France
[3] Univ Manchester, NIHR Manchester Biomed Res Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, England
[4] Kings Coll Hosp London, Kings Coll London, Dept Dermatol, London, England
[5] Prob Med Res & Alliance Clin Trials Inc, Waterloo, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] Malvern, Res, Melbourne, Australia
[8] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[9] Wake Forest Univ, Sch Med, Winston Salem, NC USA
[10] Mem Univ Newfoundland, St John, NF, Canada
[11] Pfizer Inc, Groton, CT USA
[12] Pfizer Inc, Kirkland, PQ, Canada
[13] Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 38卷 / 07期
关键词：
JANUS KINASE INHIBITOR; PLACEBO;
D O I：
10.1111/jdv.19701
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E557 / E561
页数：5
相关论文
共 50 条
  • [31] Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
    Kivitz, Alan J.
    FitzGerald, Oliver
    Nash, Peter
    Pang, Shirley
    Azevedo, Valderilio F.
    Wang, Cunshan
    Takiya, Liza
    CLINICAL RHEUMATOLOGY, 2022, 41 (02) : 499 - 511
  • [32] Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
    Strand, Vibeke
    Burmester, Gerd R.
    Zerbini, Cristiano A. F.
    Mebus, Charles A.
    Zwillich, Samuel H.
    Gruben, David
    Wallenstein, Gene V.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (04) : 475 - 483
  • [33] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Chen, Linda
    Kudlacz, Elizabeth
    Wu, Joseph
    Cappelleri, Joseph C.
    Hendrikx, Thijs
    Hsu, Ming-Ann
    RMD OPEN, 2019, 5 (01):
  • [34] Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
    Laura C. Coates
    Johan K. Wallman
    Dennis McGonagle
    Georg A. Schett
    Iain B. McInnes
    Philip J. Mease
    Lawrence Rasouliyan
    Erhard Quebe-Fehling
    Darren L. Asquith
    Andreas E. R. Fasth
    Luminita Pricop
    Corine Gaillez
    Arthritis Research & Therapy, 21
  • [35] Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
    Coates, Laura C.
    Wallman, Johan K.
    McGonagle, Dennis
    Schett, Georg A.
    McInnes, Iain B.
    Mease, Philip J.
    Rasouliyan, Lawrence
    Quebe-Fehling, Erhard
    Asquith, Darren L.
    Fasth, Andreas E. R.
    Pricop, Luminita
    Gaillez, Corine
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
  • [36] Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
    Alan J. Kivitz
    Oliver FitzGerald
    Peter Nash
    Shirley Pang
    Valderilio F. Azevedo
    Cunshan Wang
    Liza Takiya
    Clinical Rheumatology, 2022, 41 : 499 - 511
  • [37] Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
    Strand, Vibeke
    Lee, Eun Bong
    Fleischmann, Roy
    Alten, Rieke E.
    Koncz, Tamas
    Zwillich, Samuel H.
    Gruben, David
    Wilkinson, Bethanie
    Krishnaswami, Sriram
    Wallenstein, Gene
    RMD OPEN, 2016, 2 (02):
  • [38] Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
    Kristensen, Lars Erik
    Tillett, William
    Nash, Peter
    Coates, Laura C.
    Mease, Philip J.
    Ogdie, Alexis
    Gisondi, Paolo
    Ink, Barbara
    Prickett, Adam R.
    Bajracharya, Rajan
    Taieb, Vanessa
    Lyris, Nikos
    Lambert, Jeremy
    Walsh, Jessica A.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2024, 16
  • [39] Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept
    Mease, P
    Gottlieb, A
    Woolley, JM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [40] EFFICACY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS WITH INVOLVEMENT OF THE SCALP, NAILS, HANDS, AND FEET: A POOLED ANALYSIS FROM 2 PIVOTAL PHASE 3 PSORIASIS STUDIES
    Merola, Joseph F.
    Chakravarty, Soumya D.
    You, Yin
    Kafka, Shelly
    Karyekar, Chetan
    Orbai, Ana-Maria
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1855 - 1856
12345